https://www.selleckchem.com/products/vx-661.html At a median follow-up of 24 months, all patients had progressed and 6 patients were alive. Median treatment duration was 11.0 weeks (95%CI 6.0-15.9) in the regorafenib group and 6.3 weeks (95%CI 3.9-7.0) in the placebo group (p=0.002). Fourteen of 33 patients (42%) in the regorafenib group had a dose reduction. Stable disease rates were 74% (95%CI 59-90) in the regorafenib group and 34% with placebo (95%CI 18-51; p=0.002). Median PFS in the regorafenib group was 3.0 months (95%CI 2.3-4.9) and 1.5 months (95%CI 1.2-2.0) in the placebo group (hazard ratio 0.49; 95%CI 0.29-0.81; p=0.004) and median OS was 5.3 months (95%CI 2.7-10.5) and 5.1 months (95% CI 3.0-6.4), respectively (p=0.28). There were no unexpected/new safety signals. Conclusion Regorafenib significantly improved PFS and tumor control in patients with previously treated metastatic/unresectable BTC in the second- or third-line setting.Mitochondrial respiratory chain dysfunction may be predisposing for the development of migraine, reflected in high migraine prevalence in patients with mitochondrial disease. Prevalence and impact of migraine in patients with proven mitochondrial disease and the current treatment efficacy were studied using online questionnaires. Patients were selected at the Internal Medicine Department. Headache was reported by 34 (55%) out of 62 patients. Migraine-criteria were met by 85% of them. Efficacy of migraine treatment was achieved in 4 patients. Given the high prevalence of migraine and current treatment insufficiency, migraine is a major threat of quality of life patients with mitochondrial disease.Objective The optimal time after hip fracture to start prophylactic anti-osteoporosis medications (AOMs) remains uncertain, especially in real-world practice. Therefore, we investigated how timing of AOMs initiation affects the risk of subsequent osteoporotic fractures, and what factors influence timing of AOMs prescription. Method Pati